BPC-157 vs TB-500 (Thymosin Beta-4)
BPC-157 and TB-500 are two of the most widely studied peptides in tissue repair research. While both are investigated for their regenerative properties, they differ substantially in origin, mechanism, and primary research applications.
Side-by-Side Comparison
| Property | BPC-157 | TB-500 (Thymosin Beta-4) |
|---|---|---|
| Category | Gastric pentadecapeptide (body protection compound) | Thymosin beta-4 fragment (43-amino-acid peptide) |
| Mechanism of Action | Modulates nitric oxide (NO) system, upregulates growth factor expression (EGF, NGF), promotes angiogenesis | Sequesters G-actin monomers, promotes cell migration and differentiation, upregulates actin polymerization |
| Molecular Weight | ~1,419 Da (15 amino acids) | ~4,963 Da (43 amino acids) |
| Origin | Derived from human gastric juice protein BPC | Naturally occurring peptide isolated from thymus gland |
| Primary Research Focus | Gastrointestinal tissue, tendon and ligament healing, neuroprotection | Cardiac tissue repair, wound healing, anti-inflammatory activity |
| Receptor Target | No single identified receptor; modulates FAK-paxillin and JAK-2/STAT-3 pathways | Interacts with actin cytoskeleton; no traditional receptor-ligand binding |
| Half-Life | Stable in gastric juice (>24 hours); systemic half-life under investigation | Estimated 2-3 hours in circulation |
| Key Research Citations | Sikiric et al. (2018), J Physiol Pharmacol; Seiwerth et al. (2014), Curr Pharm Des | Goldstein et al. (2012), Expert Opin Biol Ther; Sosne et al. (2010), Ann N Y Acad Sci |
Key Differences
- BPC-157 is a synthetic pentadecapeptide derived from gastric juice, while TB-500 is a synthetic fragment of the naturally occurring 43-amino-acid thymosin beta-4 protein.
- BPC-157 research emphasizes gastrointestinal healing and tendon repair; TB-500 research focuses on cardiac tissue regeneration and wound closure.
- TB-500 functions primarily through actin regulation and cell motility, whereas BPC-157 acts through nitric oxide modulation and growth factor upregulation.
- BPC-157 demonstrates unusual stability in gastric acid, making it of interest for oral administration research. TB-500 requires parenteral delivery in most study protocols.
Research Summary
BPC-157 and TB-500 represent complementary approaches to tissue repair research. BPC-157 is distinguished by its gastric origin and multi-pathway mechanism involving nitric oxide and growth factor modulation, while TB-500 operates through actin cytoskeletal regulation. Researchers frequently study both peptides in combination protocols to evaluate potential synergistic effects across musculoskeletal, cardiovascular, and soft tissue models.
What is the difference between BPC-157 and TB-500?
BPC-157 is a synthetic pentadecapeptide derived from gastric juice that modulates nitric oxide pathways and growth factor expression, primarily studied for gastrointestinal and tendon repair. TB-500 is a fragment of thymosin beta-4 that regulates actin polymerization and cell migration, primarily studied for cardiac tissue regeneration and wound healing. They differ in origin, molecular weight (1,419 Da vs 4,963 Da), and mechanism of action.
More Comparisons
Disclaimer: All compounds referenced on this page are sold for research and laboratory use only. The comparisons presented are based on published scientific literature and are intended for educational and informational purposes. This content does not constitute medical advice. Researchers should consult primary literature and applicable regulations before designing study protocols.